Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Copay Accumulator & Maximizer Programs Threaten Access to Treatment

From the College  |  July 6, 2023

Health insurance companies and third-party benefit managers continue to use copay accumulators and maximizers to shift the cost of specialty drugs to patients, limiting their ability to access these critical treatments.

Manufacturer copay assistance programs help ensure patient access to the specialty medications that are critical to treat many rheumatic diseases. Without assistance programs, these medications are often unaffordable due to high co-insurance and other out-of-pocket costs. Traditionally, any assistance patients received through these programs was counted toward their deductible and out-of-pocket maximum limit, helping subsidize their overall healthcare costs. In recent years, however, payers have increased their use of copay accumulator and maximizer policies to limit the benefit of assistance programs and further shift costs to patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Copay accumulator policies allow patients to use copay assistance funds, but the amount patients receive does not count toward their deductibles or out-of-pocket maximums. When an accumulator is enforced, copay assistance funds are used up front and often exhausted in the middle of the plan year, leaving patients to pay out of pocket or discontinue or switch treatments.

Copay maximizers are somewhat newer but growing in popularity. These programs also prohibit manufacturer assistance funds from counting toward patients’ deductibles or out-of-pocket maximums; however, there are key differences in how the funds are applied. Maximizer programs spread the maximum value of the assistance funds equally across the plan year. Patients continue to receive copay assistance throughout the year; however, they must also continue to pay copays and/or coinsurance, resulting in higher out-of-pocket costs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR opposes insurance company rules that prevent application of copay assistance funds toward patient deductibles and out-of-pocket maximum limits. Additionally, the ACR encourages clear and transparent language about insurance programs that restrict copay assistance. The description of these programs is often ambiguous or misleading, failing to address how they will increase patients’ out-of-pocket costs and ultimately limit access.

The ACR continues to advocate against insurance programs that limit copay assistance and will encourage state and federal legislation to protect the inclusion of this assistance as part of patient deductibles and out-of-pocket maximum payments. Members are encouraged to contact [email protected] with concerns about copay accumulator or maximizer policies or any other insurance or practice-related inquiries.

Share: 

Filed under:Billing/CodingLegislation & AdvocacyPractice ManagementProfessional Topics Tagged with:ACR advocacycopay accumulatorscopay maximizersinsurance

Related Articles
    felipe caparros / shutterstock.com

    Copay Accumulator Programs Can Derail Rheumatologic Treatment Plans

    February 13, 2020

    As the medications for rheumatology become more expensive, the need for patient financial assistance becomes paramount. Unfortunately, commercially insured patients are finding it difficult to afford the exorbitant copays required by their plans, and the latest strategy of pharmacy benefit managers (PBMs) threatens to derail rheumatologic treatment goals. High deductible plans combined with copay accumulator…

    A Primer on Copay Accumulator Programs

    June 17, 2022

    The growing use of copay accumulator programs, which restrict the application of patient assistance funds toward cost-sharing requirements, hurts patient access to life-changing treatments. This was one topic discussed during the ACR’s Advocacy Leadership Conference in D.C. this May.

    ACR Leads Resolution to Address Copay Accumulator Policies at AMA House of Delegates Meeting

    November 6, 2020

    If passed, the ACR-authored resolution will direct the AMA to advocate for copay accumulator bans at state and federal levels. Several other specialties and state medical associations have joined the resolution as cosponsors.

    Walmart, Home Depot Adopt Health Insurer Tactic in Drug Copay Battle

    November 14, 2018

    NEW YORK (Reuters)—Walmart and Home Depot, two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences